Acrivon CAO has 116 shares withheld for taxes

Acrivon Therapeutics, Inc. Chief Accounting Officer Katharine Peterson reported a small tax-related share disposition.

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. Chief Accounting Officer Katharine Peterson reported a small tax-related share disposition. On the vesting of restricted stock units, 116 shares of common stock were withheld by the company to satisfy mandatory tax withholding, valued at $1.63 per share. After this withholding, Peterson directly holds 4,006 shares of Acrivon common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 116 shares

Exercise Price or Tax Liability 1 txn

Insider Peterson Katharine

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	116	$1.63	$189.08

Holdings After Transaction: Common Stock — 4,006 shares (Direct)

Footnotes (1)

1. F1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report for Katharine Peterson?

Acrivon Therapeutics reported that Chief Accounting Officer Katharine Peterson had 116 common shares withheld to cover taxes on restricted stock unit vesting. This was a tax-withholding disposition, not an open-market stock sale, and reflects routine equity compensation mechanics.

How many Acrivon Therapeutics (ACRV) shares were involved in Katharine Peterson’s Form 4 filing?

The Form 4 shows 116 shares of Acrivon common stock were disposed of through withholding. These shares were retained by the issuer to satisfy mandatory tax withholding when restricted stock units vested, rather than being sold in the market by the executive.

At what price were the withheld Acrivon Therapeutics (ACRV) shares valued in the Form 4?

The withheld 116 Acrivon Therapeutics common shares were valued at $1.63 per share. This price is used in the Form 4 to quantify the tax-withholding disposition when restricted stock units vested for Chief Accounting Officer Katharine Peterson.

How many Acrivon Therapeutics (ACRV) shares does Katharine Peterson hold after the transaction?

After the tax-withholding disposition, Katharine Peterson directly holds 4,006 shares of Acrivon Therapeutics common stock. This remaining balance reflects her direct ownership following the issuer’s withholding of 116 shares to meet mandatory tax obligations on RSU vesting.

Was the Acrivon Therapeutics (ACRV) Form 4 transaction an open-market sale by the CAO?

No, the transaction was not an open-market sale. According to the Form 4 footnote, 116 shares were withheld by Acrivon to satisfy mandatory tax withholding when restricted stock units vested, a common non-market equity compensation adjustment.

What does transaction code F mean in the Acrivon (ACRV) Form 4 for Katharine Peterson?

Transaction code F indicates a tax-withholding disposition, where shares are delivered to cover tax or exercise costs. In this case, 116 Acrivon shares were withheld by the issuer to satisfy mandatory tax withholding on the vesting of restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peterson Katharine

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/14/2026		F(1)		116	D	$1.63	4,006	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.